202 related articles for article (PubMed ID: 34417202)
41. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
[TBL] [Abstract][Full Text] [Related]
42. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
[TBL] [Abstract][Full Text] [Related]
43. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
[TBL] [Abstract][Full Text] [Related]
44. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
[TBL] [Abstract][Full Text] [Related]
45. SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve
Kano H; Ichihara E; Watanabe H; Nishii K; Ando C; Nakasuka T; Ninomiya K; Kato Y; Kubo T; Rai K; Ohashi K; Hotta K; Tabata M; Maeda Y; Kiura K
Mol Cancer Ther; 2021 Sep; 20(9):1653-1662. PubMed ID: 34158345
[TBL] [Abstract][Full Text] [Related]
46. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
47. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Donnini S; Monti M; Castagnini C; Solito R; Botta M; Schenone S; Giachetti A; Ziche M
Int J Cancer; 2007 Mar; 120(5):995-1004. PubMed ID: 17131343
[TBL] [Abstract][Full Text] [Related]
48. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.
Lombardo LJ; Lee FY; Chen P; Norris D; Barrish JC; Behnia K; Castaneda S; Cornelius LA; Das J; Doweyko AM; Fairchild C; Hunt JT; Inigo I; Johnston K; Kamath A; Kan D; Klei H; Marathe P; Pang S; Peterson R; Pitt S; Schieven GL; Schmidt RJ; Tokarski J; Wen ML; Wityak J; Borzilleri RM
J Med Chem; 2004 Dec; 47(27):6658-61. PubMed ID: 15615512
[TBL] [Abstract][Full Text] [Related]
49. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
50. An update on dual Src/Abl inhibitors.
Musumeci F; Schenone S; Brullo C; Botta M
Future Med Chem; 2012 Apr; 4(6):799-822. PubMed ID: 22530642
[TBL] [Abstract][Full Text] [Related]
51. Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells.
Radi M; Brullo C; Crespan E; Tintori C; Musumeci F; Biava M; Schenone S; Dreassi E; Zamperini C; Maga G; Pagano D; Angelucci A; Bologna M; Botta M
Bioorg Med Chem Lett; 2011 Oct; 21(19):5928-33. PubMed ID: 21856155
[TBL] [Abstract][Full Text] [Related]
52. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases.
Reeves PM; Smith SK; Olson VA; Thorne SH; Bornmann W; Damon IK; Kalman D
J Virol; 2011 Jan; 85(1):21-31. PubMed ID: 20962097
[TBL] [Abstract][Full Text] [Related]
53. Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.
Wilson C; Nicholes K; Bustos D; Lin E; Song Q; Stephan JP; Kirkpatrick DS; Settleman J
Oncotarget; 2014 Sep; 5(17):7328-41. PubMed ID: 25193862
[TBL] [Abstract][Full Text] [Related]
54. INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Yokota A; Kimura S; Masuda S; Ashihara E; Kuroda J; Sato K; Kamitsuji Y; Kawata E; Deguchi Y; Urasaki Y; Terui Y; Ruthardt M; Ueda T; Hatake K; Inui K; Maekawa T
Blood; 2007 Jan; 109(1):306-14. PubMed ID: 16954504
[TBL] [Abstract][Full Text] [Related]
55. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
56. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
Moroco JA; Baumgartner MP; Rust HL; Choi HG; Hur W; Gray NS; Camacho CJ; Smithgall TE
Chem Biol Drug Des; 2015 Aug; 86(2):144-55. PubMed ID: 25376742
[TBL] [Abstract][Full Text] [Related]
57. Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Laschi M; Bernardini G; Geminiani M; Manetti F; Mori M; Spreafico A; Campanacci D; Capanna R; Schenone S; Botta M; Santucci A
Biofactors; 2017 Nov; 43(6):801-811. PubMed ID: 28786551
[TBL] [Abstract][Full Text] [Related]
58. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Warmuth M; Simon N; Mitina O; Mathes R; Fabbro D; Manley PW; Buchdunger E; Forster K; Moarefi I; Hallek M
Blood; 2003 Jan; 101(2):664-72. PubMed ID: 12393636
[TBL] [Abstract][Full Text] [Related]
59. Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Leonard JT; Kosaka Y; Malla P; LaTocha D; Lamble A; Hayes-Lattin B; Byrd K; Druker BJ; Tyner JW; Chang BH; Lind E
Blood; 2021 Feb; 137(7):939-944. PubMed ID: 32898857
[TBL] [Abstract][Full Text] [Related]
60. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
Konig H; Holyoake TL; Bhatia R
Blood; 2008 Feb; 111(4):2329-38. PubMed ID: 18056843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
